Biorestorative Therapies Stock Today
| BRTX Stock | USD 2.40 0.05 2.13% |
Performance13 of 100
| Odds Of DistressLess than 45
|
BioRestorative Therapies is trading at 2.40 as of the 31st of January 2025; that is 2.13 percent increase since the beginning of the trading day. The stock's open price was 2.35. BioRestorative Therapies has 45 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. The performance scores are derived for the period starting the 3rd of September 2024 and ending today, the 31st of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of July 2007 | Category Healthcare | Classification Health Care |
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. The company has 6.92 M outstanding shares of which 130.21 K shares are currently shorted by private and institutional investors with about 2.87 trading days to cover. More on BioRestorative Therapies
Moving against BioRestorative Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
BioRestorative Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Board | Lance Alstodt | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBioRestorative Therapies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioRestorative Therapies' financial leverage. It provides some insight into what part of BioRestorative Therapies' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioRestorative Therapies (BRTX) is traded on NASDAQ Exchange in USA. It is located in 40 Marcus Drive, Melville, NY, United States, 11747 and employs 11 people. BioRestorative Therapies is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.64 M. BioRestorative Therapies conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.92 M outstanding shares of which 130.21 K shares are currently shorted by private and institutional investors with about 2.87 trading days to cover.
BioRestorative Therapies currently holds about 17.93 M in cash with (6.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check BioRestorative Therapies Probability Of Bankruptcy
Ownership AllocationThe market capitalization of BioRestorative Therapies is $16.64 Million. BioRestorative Therapies retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check BioRestorative Ownership Details
BioRestorative Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Tower Research Capital Llc | 2024-09-30 | 2.2 K | |
| Ubs Group Ag | 2024-09-30 | 693 | |
| Bank Of America Corp | 2024-09-30 | 42.0 | |
| Td Waterhouse Canada Inc | 2024-09-30 | 2.0 | |
| Jjj Advisors Inc | 2024-06-30 | 1.0 | |
| Wells Fargo & Co | 2024-09-30 | 0.0 | |
| Sabby Management Llc | 2024-06-30 | 0.0 | |
| Two Sigma Investments Llc | 2024-06-30 | 0.0 | |
| Geode Capital Management, Llc | 2024-09-30 | 55.7 K | |
| Stonex Group Inc | 2024-09-30 | 50.1 K | |
| Wealth Alliance, Llc | 2024-09-30 | 40 K |
BioRestorative Therapies Historical Income Statement
BioRestorative Stock Against Markets
BioRestorative Therapies Corporate Management
| Francisco Silva | VP Scientist | Profile | |
| Robert Paccasassi | Vice Compliance | Profile | |
| Stephen Kilmer | Investor Officer | Profile | |
| Wayne MD | Clinical Board | Profile | |
| Robert Kristal | Chief Officer | Profile |
Additional Tools for BioRestorative Stock Analysis
When running BioRestorative Therapies' price analysis, check to measure BioRestorative Therapies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioRestorative Therapies is operating at the current time. Most of BioRestorative Therapies' value examination focuses on studying past and present price action to predict the probability of BioRestorative Therapies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioRestorative Therapies' price. Additionally, you may evaluate how the addition of BioRestorative Therapies to your portfolios can decrease your overall portfolio volatility.